Previous studies applied genetically engineered TRAIL-secreting MSCs to modulate inflammation and target tumors and showed significant effects in control of tumor burden, metastasis and tumor-associated inflammation in malignant glioma [18], colorectal carcinoma [19], metastatic renal cell carcinoma [20], pancreatic cancer [21] and mesothelioma [22, 23]. The gene discussed is TNFSF10; the disease is neoplasm.